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Abstract
Background: Technology development to enable the culture of human prostate cancer
(PCa) progenitor cells is required for the identification of new, potentially curative therapies
for PCa.
Objective: We established and characterized patient-derived conditionally reprogrammed
cells (CRCs) to assess their biological properties and to apply these to test the efﬁcacies of
drugs.
Design, setting, and participants: CRCs were established from seven patient samples with
disease ranging fromprimaryPCa toadvancedcastration-resistantPCa (CRPC). TheCRCswere
characterized by genomic, transcriptomic, protein expression, and drug proﬁling.
Outcomemeasurements and statistical analysis: The phenotypic quantiﬁcation of the CRCs
was done based on immunostaining followed by image analysis with Advanced Cell
Classiﬁer using Random Forest supervised machine learning. Copy number aberrations
(CNAs) were called from whole-exome sequencing and transcriptomics using in-house
pipelines. Dose-response measurements were used to generate multiparameter drug
sensitivity scores using R-statistical language.
Results and limitations: We generated six benign CRC cultures which all had an androgen
receptor-negative, basal/transit-amplifying phenotype with few CNAs. In three-dimensional
cell culture, these cells could re-express the androgen receptor. The CRCs froma CRPC patient
(HUB.5) displayed multiple CNAs, many of which were shared with the parental tumor. We
carried out high-throughput drug-response studies with 306 emerging and clinical cancer
drugs.Using thebenignCRCs as controls,we identiﬁed theBcl-2 family inhibitor navitoclax as
the most potent cancer-speciﬁc drug for the CRCs from a CRPC patient. Other drug efﬁcacies
included taxanes, mepacrine, and retinoids.
Conclusions: Comprehensive cancer pharmacopeia-wide drug testing of CRCs from a CRPC
patient highlighted both known and novel drug sensitivities in PCa, including navitoclax,
which is currently being tested in clinical trials of CRPC.
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Prostate cancer (PCa) is the most common noncutaneous
malignancy and the second leading cause of cancer deaths in
men. Localized PCa is treated with surgery, radiation, or
surveillance, whereas androgen-deprivation therapy (cas-
tration) is the standard of care for advanced PCa [1,2]. Typi-
cally,mostpatients respond tocastrationasdemonstratedby
falling prostate-specific antigen (PSA) and quick relief of
symptoms [3]. Ultimately, the disease progresses (rising PSA
and/or growth of metastases) to a state called castration-
resistant prostate cancer (CRPC) [4]. At this stage, alternative
treatments available include novel drugs such as abiraterone
and enzalutamide, radium-223 (a radiopharmaceutical),
and cytotoxic drugs such as docetaxel and cabazitaxel [5–
11]. However, eventually the cancer cells become resistant to
hormonal and radiopharmaceutical treatments and the
currently available cytotoxic drugs.
The prostate gland consists of glandular epithelium in
which five cell types have been identified: basal, transit-
amplifying (TA), luminal, neuroendocrine, and stem cells
[12]. Basal cells are androgen independent and can be
characterized by their expression of cytokeratins (CK)-5 and
CK14. In contrast, luminal epithelial cells are androgen
dependent and can be identified by CK18, androgen
receptor (AR), and PSA expression. The TA cells are thought
to migrate from the basal to the luminal layer as they
differentiate and express a combination of markers
common to both cell types [12–14]. It has been suggested
that PCa may arise from the AR-negative, androgen-
independent basal stem cells, which are able to survive
during androgen deprivation therapy [12]. Furthermore,
cells expressing low amounts of AR and PSA within the
prostate have been suggested to exhibit long-term tumor-
propagating capacity and are not vulnerable to stress
caused by the androgen deprivation [15].
Establishment and maintenance of long-term ex vivo
cultures directly frompatient-derived prostate tumor tissue
samples has been very challenging, but this is starting to
change due to recent breakthroughs in two dimensional
(2D) and 3D cell culture technologies [16–18]. These new
primary culture technologies consist of either conditionally
reprogrammed cells (CRCs) cocultured as monolayers
(in 2D) with feeder cells (irradiated-3T3 mouse fibroblasts)
in the presence of a Rho-associated protein kinase inhibitor
(ROCKi) or of patient-derived spheroids or organoids
(in 3D). Importantly, these models are not established
through xenografting or exogenous gene transfer and they
could become critically important in understanding the
disease and identifying new therapeutic agents for PCa.
Here, we generated patient-derived CRCs of PCa from
castration-naı¨ve PCa to CRPC as well as from benign tissues
as controls. We characterized these CRCs with genomic,
transcriptomic, and protein expression profiling and
compared them with the parental tissues from which they
were isolated. We then performed comprehensive drug
sensitivity testing with 306 oncology drugs to identify
clinical and emerging oncology drugs that could be effective
for PCa-derived CRCs [19,20].2. Materials and methods
2.1. Tissue processing and establishment of CRCs
Prostate tissue was collected from seven patients undergoing prosta-
tectomy, transurethral resection of the prostate, or ultrasound-guided
needle biopsy at Helsinki University Hospital. Samples were obtained
from patients participating with informed consent in the Urological
Biobank Initiative (Helsinki Urological Biobank; HUB). With radical
prostatectomy patient samples, a cylinder shaped core of prostate tissue
(8-mm diameter) was cored out of the peripheral dorsal region of the
prostate and tissue was processed as illustrated in Figure 1. Primary cells
for the establishment of CRCs were isolated from the middle section of
the core. The ratio of benign and malignant cells in the parental tissue
was evaluated from tissue sections adjacent to the section used for CRC
establishment using hematoxylin and eosin staining (Supplementary
Table 1). The inclusion criteria for the patient samples included the ratio
of benign and malignant cells in the tissue; therefore, only tissues
without cancer cells were used for benign CRC establishment and tissues
with less than 15% of contaminating benign cells were used for cancer
CRC establishment. The methodology is described in more detail in the
supplementary material.
2.2. Copy number aberration analysis
Genomic DNA was extracted from parental tissues, CRCs, and germline
control blood cells using the DNeasy Blood & Tissue kit (Qiagen, Hilden,
Germany). The methodology and analysis pipeline are described in the
supplementary material.
2.3. Immunohistochemistry, immunofluorescence labeling, and
image analysis
Immunohistochemistry (IHC) and immunoﬂuorescence (IF) labeling
were performed according to standard operating procedures. Phenotypic
and apoptosis quantiﬁcation based on IF labeling coupled with
supervised machine learning image analysis were developed in-house,
as described in the supplementary material.
2.4. Drug sensitivity testing
The CRCs established from the patient samples were cultured for 3–7wk
and used for drug testing with 306 clinical (Food and Drug Administra-
tion and/or European Medicines Agency-approved) and emerging
oncology drugs as described in Pemovska et al [19]. Brieﬂy, cells were
exposed to drugs in ﬁve different concentrations for 72 h. The viability of
the CRCs was measured with CellTiter-Glo (CTG, Promega, Madison, WI,
USA). To determine whether the ROCK inhibitor (Y-27632) would affect
the sensitivity proﬁle, we performed replicate screens with and without
Y-27632 for HUB.1, HUB.2, HUB.3, and HUB.7 (Supplementary Fig. 3).
The comparison of the drug sensitivity score (DSS) between the replicate
screens showed strong correlation (R2 > 0.90, p < 0.0001), and thus to
maintain an optimal proliferative state of the CRCs (Fig. 1D). Y-27632
was present in all the subsequent tests.
2.5. Statistical analysis
The dose-response percent inhibition data points were ﬁtted into a four-
parameter logistic model to calculate IC50, slope, top, and lower
asymptotes. These parameters were used to quantify the drug response,
using a multiparameter area under the curve sensitivity calculation
called the DSS. The DSS was calculated for each drug and compared
between the averaged controls and CRCs to obtain patient speciﬁc DSS
[(Fig._1)TD$FIG]
Fig. 1 – Diagram of tissue processing and establishment of conditionally reprogrammed cells (CRCs). (A) The peripheral tissue pieces of the prostate
tissue sample were snap-frozen and used for genomic and transcriptomic profiling. Adjacent tissue pieces were fixed in 10% buffered formalin and
used for histological evaluation (hematoxylin and eosin; HE) and protein expression profiling by immunohistochemistry. The CRC cultures were
initiated from the middle section of the prostate tissue sample. The tissue was mechanically and enzymatically dissociated and cocultured with
inactivated 3T3 feeder cells in Rho-associated protein kinase inhibitor (ROCKi; Y-27632) supplemented medium until entering the genomic,
transcriptomic, protein expression, and drug sensitivity profiling. (B) A representation of HE based histological evaluation of parental benign tissue
and tumor tissue used for determining the histological origin of CRCs. The representative images were obtained using 40T objective and the scale bar
indicates 100 mm. (C) A light microscope image of CRCs and 3T3 feeder cells (white arrows). The image was taken with 20T objective. (D) A growth
curve of CRCs grown for 96 h with both feeder cells (3T3) and ROCKi in F-medium (blue line), with feeder cells only in F-medium (orange line), with
ROCKi only in F-medium (green line), and with F-medium without feeders and ROCKi (purple line). Error bars indicate the standard deviation of at
least triplicate wells.
FFPE = formalin-fixed, paraffin-embedded.
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coefﬁcient was used to assess the signiﬁcance of correlations displayed
in the XY plots across drug sensitivity and GraphPad Prism 6 (GraphPad
Software Inc., La Jolla, CA, USA) was used to generate these plots as well
as the combined dose-response curve ﬁts illustrated in Supplementary
Figure 4A. The R statistical programming language and the heatmap
function from Heatplus Bioconductor package (v.2.15.3, http://www.
r-project.org/) were used to generate the selective DSS heatmap.
Clustering of the drug sensitivity proﬁles across the samples was done
with unsupervised hierarchical clustering based on the Ward-linkage
method and Spearman’s rank as the distance metric.
3. Results
3.1. Prostate tissue processing and establishment of the CRC
cultures
For this study, we selected seven patients whose disease
ranged from benign to early prostate cancer and CRPC
(HUB.1–7; Table 1). Based on the histological evaluation,
altogether seven tumor and two benign samples were used
for the establishment of CRCs (Table 1, Fig. 1A and 1B,
Supplementary Table 1). The CRCs were generated through
coculturing of freshly isolated patient cells and feeder cells
in culture medium supplemented with ROCKi [16]. In this
system patient-derived CRCs grow in colonies typical of
epithelial cells (Fig. 1C). The optimal growth conditions for
the CRCs were tested in live phase contrast imaging in four
different conditions: (1) with both feeder cells and ROCKi,
(2) with feeder cells only, (3) with ROCKi only, and (4)
without feeder cells and ROCKi. The results show that both
feeder cells and ROCKi were necessary for the optimal cell
growth (Fig. 1D). Seven out of nine (78%) attempts to start
CRC cultures were successful. The CRCs were characterized
with genomic, transcriptomic, and protein expression
profiling, and compared with the parental tissue from
which the benign and cancer cells were isolated (Supple-
mentary Table 2).
3.2. Molecular characteristics of the CRCs
To define and quantify the phenotypic variation in the CRCs,
we performed IF labeling of the cells coupled with
supervised machine learning image analysis using five
classifiers: (1) cell nuclei, (2) basal cells (CK5/p63 positive),
(3) luminal cells (CK18 positive), and (4) TA cells (CK5/p63
and CK18 positive), as well as (5) other types. We observedTable 1 – Patient characteristics and initiated conditionally reprogram
Patient Gleason score PSA (ng/ml) TNM Previou
HUB.1 4 + 5 = 9 (70%) 15.5 pT3bN0M0 –
HUB.2 4 + 5 = 9 (30%) 7.53 pT3aN0M0 –
HUB.3 4 + 5 = 9 (10%) 8.54 pT3N1M0 –
HUB.4 5 + 4 = 9 (90%) 92 cT3N0M0 Orchiectomy, bic
HUB.5 5 + 4 = 9 (80%) 1.67 cT4N1M1 LH-RH-agonist, b
abiraterone
HUB.6 3 + 4 = 7 (24%) 4.06 cT3N0M0 External radiatio
HUB.7 4 + 4 = 8 (NA) 2.96 cT4N1M1 Orchiectomy, pa
HUB = Helsinki Urological Biobank; LH-RH-agonist = luteinizing hormone-releas
RALP = robotic-assisted laparoscopic prostatectomy; TURP = transurethral resectibasal cell markers p63/CK5 and luminal cell marker CK18
being expressed either alone or simultaneously (TA
phenotype) in all CRCs (Fig. 2A and 2B). Five out of seven
(71%) CRCs were dominated by the TA phenotype whereas
in two CRCs (HUB.1 and HUB.5), the basal phenotype was
more prominent. Additionally, HUB.3.CC displayed a strong
luminal population (45%). We confirmed the expression of
these cell type-specific markers using western blotting and
IHC of formalin-fixed, paraffin-embedded samples from the
corresponding tissue and CRCs (Fig. 2C and 2D, Supplemen-
tary Fig. 1).
All the CRCs were found to be AR and PSA negative in
contrast to their parental tissue (Fig. 2C and 2D, Supple-
mentary Fig. 1), which was also confirmed by RNA-
sequencing and quantitative polymerase chain reaction
(data not shown). We were able to restore AR expression in
HUB.1 CRCs when grown in 3D spheroid culture (Fig. 2E),
whereas the CRPC-derived HUB.5 CRCs were not able to
grow as spheroids (data not shown).
Genomic analysis was performed to identify cancer-
specific copy number aberrations (CNAs) in the CRCs and
compare these with the CNAs found in the parental tissue.
Most of the CRCs had no shared CNAs with the matching
parental tissue, suggesting that they represented benign
cells (Supplementary Fig. 2A). In contrast, HUB.5 CRCs
shared the same cancer-specific deletions at chromosomes
1p and 16p with their parental tumor tissue (Fig. 2F,
Supplementary Fig. 2B). A full list of HUB.5 CRC-specific
somatic mutations is provided in Supplementary
Table 3. Thus, the HUB.5 CRC model appears to be a bona
fide PCa CRC model established in this study.
3.3. Comprehensive oncology drug testing in the CRPC-derived
HUB.5 CRCs
To identify vulnerabilities of HUB.5 CRCs towards oncology
drugs we performed drug testing using 306 oncology drugs
in five different concentrations and measured cell viability
after 72 h of drug exposure [19,20] (Supplementary
Table 4). To obtain a HUB.5 cancer-selective sensitivity
profile, we used two sets of controls, the first set with the
mean of two CRC models derived from benign prostate
tissue (HUB.2.BC and HUB.3.BC) and the second set with the
mean of all other CRCs established in this study, except for
HUB.5. The results from both sets of controls showed
cancer-specific DSS for HUB.5 for several drugs thatmed cells (CRC)
s treatments Tissue source Benign CRC Cancer CRC
RALP – 1
RALP 1 1
RALP 1 1
alutamide TURP – 1
icalutamide, docetaxel, TURP – 1
n and bicalutamide Needle biopsy – 1
lliative TURP Needle biopsy – 1
ing hormone agonist; NA = not applicable; PSA = prostate-speciﬁc antigen;
on of the prostate.
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Fig. 2 – Characterization of conditionally reprogrammed cells (CRCs) and the parental tissue. (A) Representative immunofluorescence images of the
CRCs showing phenotypic classifiers for basal (cytokeratin [CK]-5; red), transit-amplifying (TA; CK5 and CK18; yellow), and luminal cells (CK18; green).
The nuclei were counterstained with Hoechst 33342 for DNA. The images were taken with 60T objective and the scale bar indicates 10 mm. (B)
Phenotypic quantification of basal, TA, and luminal populations of the given patient-derived samples excluding mitotic, abnormal, and feeder cells
shown in percentages. A total of 145 to 566 cells were analyzed per sample. BC and CC indicates CRCs isolated from benign areas and malignant areas
respectively. (C) Immunohistochemistry staining of castration-resistant prostate cancer [4_TD$DIFF]HUB.5[3_TD$DIFF] tissue and CRCs with the indicated markers. Images of
representative fields were captured at 20T (tissue) and 40T (cytoblock) magnification and the scale bars indicate 100 mm (tissue) and 20 mm
(cytoblock). (D) Western blotting analysis of HUB.5 CRCs and control cell lines with the following markers: p63, CK5, CK18, androgen receptor (AR),
prostate-specific antigen (PSA), and actin. (E) Immunohistochemistry staining of AR expression in HUB.1 tissue, CRCs, and spheroids. The scale bars
indicate 100 mm (tissue), 20 mm (cytoblock), and 100 mm (spheroid). (F) Visualization of the HUB.5 parental tissue and CRCs showed similar copy
number aberrations (CNAs) at chromosomes 1p, 2q, 7p, 7q, 8p, 14q, 15q, and 16p with exact breakpoint matches at chromosomes 1p and 16p. Red
color represents copy number gains and blue deletions.
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Fig. 3 – Comprehensive drug testing identified sensitivity profiles for the conditionally reprogrammed cells (CRCs). (A) Correlation plot of the drug
sensitivity score (DSS) between [4_TD$DIFF]HUB.5[3_TD$DIFF] CRCs (y-axis) and the mean DSS value of two CRCs derived from benign prostate tissue (HUB.2.BC and HUB.3.BC),
and (B) mean DSS of all other CRCs (HUB.1–3 and HUB.7) established in this study except for HUB.5 CRCs plotted on the x-axis. (C) Unsupervised
hierarchical clustering of patient specific DSS compared with benign controls (HUB.2.BC and HUB.3.BC). Red represents higher DSS or decreased cell
viability whereas blue represents lower DSS or higher viability in comparison to the average of two controls. The heat map has been classified into
four (1–4 as indicated) distinct patterns based on HUB.5 CRCs’ drug responses. The arrows indicate navitoclax, bexarotene, tretinoin, oxaplatin,
docetaxel, and mepacrine.
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 3 1 9 – 3 2 7324included navitoclax, bexarotene, tretinoin, oxaliplatin, and
mepacrine (Fig. 3A and 3B, Supplementary Table 4).
Unsupervised hierarchical clustering was applied to
compare the overall drug response profile of theHUB.5 CRCs
with all the other CRCs, aswell as to the commonly used PCa
cell lines LNCaP, LAPC4, PC3, and VCaP (Fig. 3C). Altogether,
46 drugs were more effective in HUB.5 CRCs than the mean
of the controls and six drugs showed lower efficacy
(Supplementary Table 4B). HUB.5 CRCs clustered together
with the PCa cell lines VCaP and LNCaP, whereas the
other CRCs formed a distinct cluster. Of the drugs
highlighted, oxaliplatin and docetaxel as well as mepacrine(an antimalaria drug) have been tested in clinical trials for
CRPC (clinicaltrials.gov; NCT00260611, NCT01487720,
NCT00417274). Gemcitabine also showed high efficacy in
HUB.5 CRCs (cluster 3) and the combination of gemcitabine
with oxaliplatin has been suggested as a second-line
treatment option for metastatic CRPC after failure of
docetaxel [21]. Interestingly, docetaxel and paclitaxel are
found in cluster 4 along with navitoclax, which was the
most effective targeted drug and themost specific for HUB.5
CRCs (Fig. 3A and 3B, Supplementary Table 4). Navitoclax
in combination with abiraterone is currently undergoing
phase II trials for metastatic CRPC (NCT01828476).
E U RO P E AN URO L OGY 7 1 ( 2 0 1 7 ) 3 1 9 – 3 2 7 3253.4. Navitoclax induces apoptosis in CRPC-derived HUB.5 CRCs
RNA sequencing data indicated elevated expression of Bcl-2
family members Bcl-xL and Mcl-1 in both HUB.5 tumor
tissue and CRCs (Fig. 4A). These findingwere validated using
quantitative polymerase chain reaction and IHC for Bcl-xL
[(Fig._4)TD$FIG]Fig. 4 – The expression of Bcl-2 family members and impact of navitoclax in ca
cells (CRCs). (A) RNA sequencing results of the Bcl-2 family members in [4_TD$DIFF]HUB.5
fragments mapped values. (B) Real-time quantitative reverse transcription pol
RNA sequencing data. The expression was normalized to the average of four h
Error bars are representing theW standard deviation of two independent techn
and Mcl-1 in HUB.5 tissue and CRCs. The representative images were obtained
representative image showing the HUB.5 response to navitoclax. Red immunof
after 24 h exposure to navitoclax (280 nM). Blue color indicates nuclei stained
the scale bar indicates 10 mm. (E) Quantification of the apoptotic cells (as show
analyzed per sample. (F) Western blotting analysis of cCaspase-3 and actin as a
(280 nM) exposure. Dimethyl sulfoxide was used as control vehicle in D and F.and Mcl-1 (Fig. 4B and 4C). To validate the navitoclax
sensitivity of HUB.5 CRCs, we quantified the apoptotic cells
by the expression of cleaved Caspase-3 under navitoclax
exposure using IF labeling and supervisedmachine learning
image analysis. These results show an increase in cleaved
Caspase-3-positive cells after 24–72 h of navitoclaxstration-resistant prostate cancer derived conditionally reprogrammed
[3_TD$DIFF] tissue and CRCs presented in fragments per kilobase of exon per million
ymerase chain reaction analysis of the Bcl-2 family members to verify
ousekeeping (HK) genes (18S ribosomal RNA, B2 M, RPLPO, and ACTB).
ical replicate experiments. (C) Immunohistochemistry staining of Bcl-xL
using 40T objective and the scale bar indicates 20 mm. (D) A
luorescence staining indicates the cleavage of Caspase-3 in HUB.5 CRCs
with Hoechst 33342. The images were obtained using 40T objective and
n in D) by cCaspase-3 and DNA labeling. A total of 376 to 776 cells were
loading control in HUB.5 CRCs after 24 h, 48 h, and 72 h of navitoclax
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 3 1 9 – 3 2 7326treatment compared with mock treated cells (Fig. 4D and
4E). Similarly, western blotting analysis validated the
apoptotic response of navitoclax showing cleavage of
caspase-3 only in HUB.5 CRCs (Fig. 4F), and not in two
other CRCs (HUB.1 and HUB.3.CC) which were also resistant
to navitoclax in the primary testing (Supplementary Fig. 4A
and 4B). Together, these results show that navitoclax,
initially identified through drug testing, is effective in
inducing apoptosis in the CRPC-derived HUB.5 CRCs. HUB.5
CRCs’ sensitivity to navitoclax is consistent with the protein
expression profile showing increased expression of Bcl-2
family members Bcl-xL and Mcl-1 (Fig. 4C).
4. Discussion
We had almost 80% success in establishing ex vivo CRC
cultures from prostate tissues, including one CRC culture
with a clonal relationship to the original tumor tissue was
established from a patient with CRPC (HUB.5). The patient
with a more clinically aggressive disease (HUB.5) had a
relatively homogenous cancer content with no benign cells
present in the parental tissue specimen. This sample gave
rise to CRCs presenting shared CNAs with the parental
tissue, while most other PCa samples gave rise to
genomically normal, likely benign cell cultures.
Themajority of the CRCswere identified as TA,which is in
agreementwith thepresumedcell type that acts as aprostate
progenitor [22]. TA cells are androgen-independent and do
not express AR or PSA, but this phenotype is transitory and
the cells differentiate to express luminal markers in
appropriate growth conditions. AR and PSA negative cancer
cells have been suggested to exhibit long-term tumor-
propagating capacity, and they are refractory to androgen
deprivation and consequently evade apoptosis during
treatment [15]. Moreover, these types of cells have been
suggested to repopulate the tumors after antiandrogen
treatment. Similarly, high expression of the prosurvival
Bcl-2 family members (Bcl-2 and Bcl-xL) is frequent in
advanced PCa and has been linked to drug resistance
[23]. Therefore, targeting the expression of Bcl-2 family
members, for example, Bcl-2, Bcl-xL, Bcl-W, andMcl-1, could
sensitize cells to chemotherapy [23–25]. The comprehensive
drug testing identified several clinical and emerging drugs
showing selective efficacy against the CRPC-derived HUB.5
CRCs (Fig. 3). Importantly, we were able to find efficacies for
nonhormonal drugs such as taxanes, which are commonly
used in clinical practice, aswell as lesswell-established anti-
PCa drugs such as mepacrine, oxaliplatin, and navitoclax,
many ofwhich are also currently undergoing clinical trials in
different combinations for CRPC. Indeed, the drug sensitivity
profile identified for HUB.5 CRCs—the CRPC culture estab-
lished in this study—provides both validation of the efficacy
of existing and emerging anti-PCa drugs as well as generates
starting points for new drug repositioning efforts in CRPC.
Thus, our approach to combine novel methods for culturing
PCa primary cells with high-throughput drug testing
technology provides insights for drug development,
drug repositioning, and possibly in the future, precision
oncology.5. Conclusions
Better functional understanding of cell signaling and drug
vulnerabilities in clinical human PCa tissues is urgently
required to enable therapeutic discoveries. This study
provides proof of concept for establishing CRCs from CRPC
patients. Drug sensitivity testing of these CRPC-derived
CRCs highlighted sensitivity to several potential oncology
drugs such as taxanes, mepacrine, oxaliplatin, and navito-
clax. The most potent effects were seen with navitoclax,
which was linked to the overexpression of Bcl-2 family
members and induction of apoptosis.
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